| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|---|---|
Cash Flows from Operating Activities: | ||||||||||
Cash flows from operating activities: | ||||||||||
Net loss | ||||||||||
-32,141 | -32,575 | -53,317 | -60,411 | -58,981 | -18,729 | -12,322 | -16,416 | -9,858 | -4,435 | -9,822 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||
Depreciation and amortization | ||||||||||
125 | 200 | 200 | 193 | 161 | 155 | 141 | 126 | 107 | 686 | 751 |
Non-cash lease expense | ||||||||||
956 | 0 | - | - | - | - | - | - | - | - | - |
Stock-based compensation expense | ||||||||||
2,658 | 3,940 | 5,359 | 4,325 | 3,875 | 3,060 | 3,002 | 3,623 | 1,772 | 1,967 | 1,854 |
Issuance of common stock in consideration for rights granted under the Aurigene collaboration agreement (see Note 3(b)) | ||||||||||
- | - | - | 17,989 | 23,968 | 0 | - | 964 | - | - | - |
Change in fair value of warrant liability | ||||||||||
- | - | - | - | - | -717 | -771 | -2,257 | 2,756 | - | - |
Amortization of debt issuance costs | ||||||||||
8 | 35 | 144 | 48 | 56 | 89 | 104 | 5 | - | - | - |
Non-cash imputed interest expense related to the sale of future royalties | ||||||||||
287 | 0 | - | - | - | - | - | - | - | - | - |
Change in fair value of warrant liability | ||||||||||
- | - | - | - | - | - | - | - | - | 575 | - |
Non-cash interest expense on investments | ||||||||||
64 | 147 | 53 | -168 | -149 | -170 | -95 | 434 | -246 | 316 | - |
Gain (Loss) on Extinguishment of Debt | ||||||||||
-3,495 | 0 | - | - | - | - | - | - | - | - | - |
Non-cash interest on debt | ||||||||||
- | - | - | - | - | -714 | 713 | - | - | - | - |
Loss on disposal of fixed assets | ||||||||||
-29 | -7 | 0 | 0 | 22 | 2 | - | - | 77 | 98 | - |
Changes in operating assets and liabilities: | ||||||||||
Impairment on property and equipment | ||||||||||
- | - | - | - | - | - | - | - | - | - | 1 |
Accounts receivable | ||||||||||
380 | -209 | 614 | 353 | 145 | 484 | 569 | 865 | -50 | -423 | 408 |
Prepaid expenses, and other assets | ||||||||||
237 | -162 | -267 | 85 | 726 | 2 | 116 | -40 | -24 | -239 | 253 |
Accounts payable and accrued and other liabilities | ||||||||||
60 | -1,873 | -376 | 2,315 | 1,774 | 361 | 181 | 20 | 416 | 955 | -186 |
Operating lease liability | ||||||||||
-1,001 | 0 | - | - | - | - | - | - | - | - | - |
Deferred revenue | ||||||||||
- | - | - | - | - | - | - | - | - | -475 | 475 |
Total adjustments | ||||||||||
5,936 | 2,510 | 4,962 | 24,600 | 29,090 | 1,916 | 2,782 | 1,223 | 5,295 | 2,806 | 2,234 |
Net cash used in operating activities | ||||||||||
-26,200 | -30,065 | -48,355 | -35,811 | -29,891 | -16,813 | - | - | -4,563 | -1,629 | -7,588 |
Net cash used in operating activities | ||||||||||
- | - | - | - | - | - | -9,539 | -15,193 | - | - | - |
Cash flows from investing activities: | ||||||||||
Cash flows from investing activities: | ||||||||||
Purchases of investments | ||||||||||
11,465 | 26,741 | 51,121 | 57,639 | 123,240 | 41,399 | 65,827 | 69,153 | 42,136 | 65,897 | 35,825 |
Sales and maturities of investments | ||||||||||
7,050 | 48,200 | 47,679 | 88,092 | 116,822 | 57,749 | 52,349 | 46,214 | 51,834 | 51,464 | 36,669 |
Decrease in restricted cash/investments | ||||||||||
- | - | - | 0 | -14 | -14 | -13 | -41 | -261 | 281 | 5 |
Purchase of property and equipment | ||||||||||
41 | 85 | 188 | 329 | 48 | 92 | 153 | 104 | 260 | 274 | 19 |
Proceeds from sale of fixed assets | ||||||||||
- | - | - | 0 | 24 | 1 | - | - | 77 | 99 | - |
Net cash provided by investing activities | ||||||||||
-4,456 | 21,374 | -3,630 | 30,124 | -6,428 | 16,273 | - | - | 9,775 | -14,889 | 818 |
Net cash (used in)/provided by investing activities | ||||||||||
- | - | - | - | - | - | -13,617 | -23,003 | - | - | - |
Cash flows from financing activities: | ||||||||||
Cash flows from financing activities: | ||||||||||
Proceeds from issuance of common stock associated with offerings, net of issuance costs (see Note 9) | ||||||||||
- | - | - | - | - | - | - | 879 | 288 | 14,942 | - |
Sale of common stock | ||||||||||
- | - | 41,546 | 0 | 64,620 | 0 | 16,245 | 5,105 | 1,792 | 2,127 | 3,886 |
Proceeds from royalty interest purchase agreement with Oberland Capital Management, LLC | ||||||||||
65,000 | 0 | - | - | - | - | - | - | - | - | - |
Payment of issuance costs on royalty interest purchase agreement | ||||||||||
584 | 0 | - | - | - | - | - | - | - | - | - |
Proceeds from issuance of common stock under the Company’s stock-based compensation plans | ||||||||||
68 | 143 | 1,138 | 2,907 | 1,206 | 283 | 4,016 | - | - | - | - |
Payment of liability of future royalties, net of imputed interest | ||||||||||
2,226 | 0 | - | - | - | - | - | - | - | - | - |
Proceeds from new credit agreement with HealthCare Royalty | ||||||||||
- | - | 45,000 | 0 | 0 | - | - | - | - | - | - |
Payment of debt issuance costs | ||||||||||
- | - | 192 | 0 | 0 | - | 261 | 160 | - | - | - |
Payment on termination of credit agreement with HealthCare Royalty Partners, III, L.P. | ||||||||||
37,162 | 0 | 18,303 | 0 | 0 | - | - | - | - | - | - |
Repayments of Debt | ||||||||||
1,825 | 6,104 | 4,954 | 4,273 | 4,163 | 1,587 | - | - | - | - | - |
Net cash provided by financing activities | ||||||||||
23,271 | -5,961 | 64,235 | -1,366 | 61,663 | -1,304 | - | - | 2,080 | 17,069 | 3,886 |
Net decrease in cash and cash equivalents and restricted cash | ||||||||||
-7,390 | -14,652 | - | - | - | - | - | - | - | - | - |
Payments on Curis Royalty's debt | ||||||||||
- | - | - | - | - | - | - | 30,000 | - | - | - |
Net cash (used in)/provided by financing activities | ||||||||||
- | - | - | - | - | - | 20,000 | 35,824 | - | - | - |
Net (decrease)/increase in cash and cash equivalents | ||||||||||
- | - | 12,250 | -7,053 | 25,344 | -1,844 | -3,156 | -2,372 | 7,293 | 551 | -2,883 |
Supplemental cash flow data: | ||||||||||
Cash paid for interest | ||||||||||
4,716 | 3,919 | 3,942 | - | - | - | - | - | - | - | - |
Cash paid for interest | ||||||||||
- | - | - | 2,787 | 3,303 | 4,386 | 2,913 | - | - | - | - |
Treasury stock | ||||||||||
- | - | - | - | - | - | 632 | - | - | - | - |
Receivable for issuances of common stock | ||||||||||
- | - | - | - | - | - | - | 14 | 375 | - | - |
Unpaid debt issuance costs | ||||||||||
- | - | - | - | - | - | - | 261 | - | - | - |